Physician profile
Matthew B Hendricks
NPI 1821638404
$5,398.85
in general payments reported to CMS, 2019-2025
25 companies · $14.81 in 2025
The $14.81 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,427 · 2022: $1,891 · 2023: $775 · 2024: $291 · 2025: $14.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.26 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,196.25 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $539.22 | 2021-2023 | Rexulti, Nuedexta |
| Sunovion Pharmaceuticals INC. | $534.82 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $485.53 | 2021-2023 | Trintellix |
| Axsome Therapeutics, INC. | $426.17 | 2022-2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $378.71 | 2021-2023 | Hetlioz, Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $335.00 | 2021-2023 | |
| Alkermes, INC. | $331.72 | 2021-2023 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $211.44 | 2021-2023 | Ingrezza |
| Lundbeck LLC | $194.44 | 2021-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $143.51 | 2021-2023 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $138.66 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $125.57 | 2021-2022 | |
| Bausch Health US, LLC | $100.31 | 2021-2023 | Aplenzin |
| Gilead Sciences, INC. | $46.27 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $41.49 | 2021 | |
| Corium, LLC | $30.40 | 2022-2023 | Azstarys |
| Eisai INC. | $29.05 | 2021-2022 | |
| Almatica Pharma LLC | $28.97 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $17.40 | 2023 | Qelbree |
| Neos Therapeutics, LP | $13.33 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.28 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $12.76 | 2021 | |
| Aytu Biopharma, INC. | $12.72 | 2021 | |
| Allergan, INC. | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hendricks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.